DeepMed Research

RHODES PHARMACEUTICALS L.P.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Flexible-Dose Titration Study of Aptensio XR in Children Ages 4 to Under 6 Years Diagnosed With ADHD

Phase 4

Completed

Conditions: Attention Deficit Disorder With Hyperactivity

Interventions: Drug: Aptensio XR
Drug: Placebo

First Posted Date: 2016-02-17

Last Posted Date: 2023-02-21

Lead Sponsor: Rhodes Pharmaceuticals, L.P.

Target Recruit Count: 158

Registration Number: NCT02683265

Locations: 🇺🇸
Center for Psychiatry and Behavioral Medicine Inc., Las Vegas, Nevada, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD

Phase 4

Conditions: Attention Deficit Disorder With Hyperactivity

Interventions: Drug: Aptensio XR

First Posted Date: 2016-02-09

Last Posted Date: 2016-08-25

Lead Sponsor: Rhodes Pharmaceuticals, L.P.

Target Recruit Count: 120

Registration Number: NCT02677519

Locations: 🇺🇸
Center for Psychiatry and Behavioral Medicine Inc., Las Vegas, Nevada, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD

Phase 3

Completed

Conditions: Attention Deficit Hyperactivity Disorder

Interventions: Drug: Placebo
Drug: lisdexamfetamine dimesylate
Drug: PRC-063

First Posted Date: 2015-09-21

Last Posted Date: 2017-01-19

Lead Sponsor: Rhodes Pharmaceuticals, L.P.

Target Recruit Count: 40

Registration Number: NCT02555150

Locations: 🇺🇸
University of Virginia, Charlottesville, Virginia, United States

Pharmacokinetic Study of Methylphenidate HCl Extended-Release Capsules in Children 4 to Under 6 Years of Age With ADHD

Phase 4

Completed

Conditions: Attention-Deficit/Hyperactivity Disorder

Interventions: Drug: Methylphenidate HCl ER Capsules, 10 mg
Drug: Methylphenidate HCl ER Capsules, 20 mg
Drug: Methylphenidate HCl ER Capsules, 15 mg

First Posted Date: 2015-06-12

Last Posted Date: 2021-11-24

Lead Sponsor: Rhodes Pharmaceuticals, L.P.

Target Recruit Count: 10

Registration Number: NCT02470234

Locations: 🇺🇸
Qps-Mra, Llc, South Miami, Florida, United States
🇺🇸
Duke Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, North Carolina, United States

PRC-063 in an ADULT Workplace Environment

Phase 3

Completed

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)

Interventions: Drug: PRC-063 25 mg
Drug: Placebo
Drug: PRC-063 35 mg
Drug: PRC-063 45 mg
Drug: PRC-063 55 mg
Drug: PRC-063 70 mg
Drug: PRC-063 85 mg
Drug: PRC-063 100 mg

First Posted Date: 2014-08-26

Last Posted Date: 2015-07-09

Lead Sponsor: Rhodes Pharmaceuticals, L.P.

Target Recruit Count: 60

Registration Number: NCT02225639

Locations: 🇺🇸
AVIDA, Inc., Newport Beach, California, United States
🇺🇸
Center for Psychiatry and Behavioral Medicine Inc., Las Vegas, Nevada, United States

Long-Term Safety of PRC-063 in Adolescents and Adults With ADHD

Phase 3

Completed

Conditions: ADHD

Interventions: Drug: PRC-063

First Posted Date: 2014-06-20

Last Posted Date: 2015-07-08

Lead Sponsor: Rhodes Pharmaceuticals, L.P.

Target Recruit Count: 360

Registration Number: NCT02168127

Locations: 🇺🇸
Wake Research Associates, Raleigh, North Carolina, United States
🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸
Houston Clinical Trials, Houston, Texas, United States

and more 30 locations

The Efficacy and Safety of PRC-063 in Adult ADHD Patients

Phase 3

Completed

Conditions: ADHD

Interventions: Drug: Placebo
Drug: PRC-063 25 mg
Drug: PRC-063 45 mg
Drug: PRC-063 70 mg
Drug: PRC-063 100 mg

First Posted Date: 2014-05-15

Last Posted Date: 2019-05-07

Lead Sponsor: Rhodes Pharmaceuticals, L.P.

Target Recruit Count: 375

Registration Number: NCT02139124

Locations: 🇺🇸
Princeton Medical Institute, Princeton, New Jersey, United States
🇺🇸
Clinical Neuroscience Solutions Inc., Memphis, Tennessee, United States
🇺🇸
Stedman Clinical Trials, Tampa, Florida, United States

and more 33 locations

PRC-063 in Adolescent ADHD

Phase 3

Completed

Conditions: ADHD

Interventions: Drug: Placebo
Drug: PRC-063 25 mg
Drug: PRC-063 45 mg
Drug: PRC-063 70 mg
Drug: PRC-063 85 mg

First Posted Date: 2014-05-15

Last Posted Date: 2015-07-08

Lead Sponsor: Rhodes Pharmaceuticals, L.P.

Target Recruit Count: 360

Registration Number: NCT02139111

Locations: 🇺🇸
Advanced Clinical Research, Boise, Idaho, United States
🇺🇸
Red Oak Psychiatry Associates, Houston, Texas, United States
🇺🇸
Houston Clinical Trials, Houston, Texas, United States

and more 39 locations

Safety and Efficacy of PG101 for Dry Eye Syndrome

Phase 1

Completed

Conditions: Dry Eye Syndrome

Interventions: Drug: PG101

First Posted Date: 2014-03-05

Last Posted Date: 2014-03-05

Lead Sponsor: Rhodes Pharmaceuticals, L.P.

Target Recruit Count: 72

Registration Number: NCT02078661

Locations: 🇺🇸
Andover Eye, Andover, Massachusetts, United States

Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom Setting

Phase 3

Completed

Conditions: Attention Deficit Hyperactivity Disorder
ADHD

Interventions: Drug: Methylphenidate Hydrochloride Extended Release Capsule
Drug: Placebo

First Posted Date: 2011-01-04

Last Posted Date: 2022-12-13

Lead Sponsor: Rhodes Pharmaceuticals, L.P.

Target Recruit Count: 26

Registration Number: NCT01269463

Locations: 🇺🇸
University of California, Irvine/Child Development Center, Irvine, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy